➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Dow
Medtronic
Harvard Business School
Baxter

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Epoetin alfa - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for epoetin alfa

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Health Research Board, IrelandPhase 3
Medical Research Future Fund (MRFF)Phase 3
University College DublinPhase 3

See all epoetin alfa clinical trials

Recent Litigation for epoetin alfa

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ameranth, Inc. v. Starbucks Corporation2013-05-06

See all epoetin alfa litigation

Pharmacology for epoetin alfa
Physiological EffectIncreased Erythroid Cell Production
Established Pharmacologic ClassErythropoiesis-stimulating Agent
Chemical StructureErythropoietin
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for epoetin alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for epoetin alfa Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 ⤷  Free Forever Trial 2012-08-15 Company disclosures
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 ⤷  Free Forever Trial 2013-08-20 Company disclosures
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 ⤷  Free Forever Trial 2003-12-13 Company disclosures
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 ⤷  Free Forever Trial 2015-05-26 Company disclosures
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 ⤷  Free Forever Trial 2016-09-21 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for epoetin alfa Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for epoetin alfa

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SPC/GB01/055 United Kingdom ⤷  Free Forever Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTERED: UK EU/1/01/185/001-030 20010608
300075 Netherlands ⤷  Free Forever Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608
01C0050 France ⤷  Free Forever Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608
10199059 Germany ⤷  Free Forever Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
McKinsey
Medtronic
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.